• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Impax Laboratories

edit

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals. In the generic pharmaceuticals market, the Company focuses on controlled-release generic versions of brand-name pharmaceuticals, covering a range of therapeutic areas. In the brand-name pharmaceuticals market, the Company is developing products for the treatment of central nervous system (CNS) disorders. The Company’s brand-name product portfolio consists of development-stage projects to which the Company applies its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. It operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division).

Recent Milestones

edit

• 
  Impax Laboratories — Impax snares $186M deal from GSK on late-stage Parkinson's drug (12/16/10)
  Posted 12/16/10 at 8:52pm via fiercebiotech.com
• 
  Impax Laboratories added Larry Hsu as President, CEO, Director .
  Posted 12/16/10 at 8:50pm
• 
  Went public with stock symbol NASDAQ:IPXL.
  Posted 12/16/10 at 8:51pm
• 
  Impax Laboratories added Arthur A. Koch Jr. as CFO.
  Posted 12/16/10 at 8:50pm

Videos

Screenshots

edit

Stock Price

Sources

Impax snares $186M deal from GSK on late-stage Parkinson's drug (fiercebiotech.com) [edit]